FDA Approves Generic Version of Twice-Yearly HIV Prevention Shot Lenacapavir

The U.S. Food and Drug Administration has approved a generic version of lenacapavir, which is described as the world's only twice-a-year shot to prevent HIV. The announcement was made on Monday morning. The approval is described as a big step toward making the drug available both inexpensively and more quickly in 120 low- and middle-income countries. The story's shared headline says the approval raises hopes in low-income countries. The available text does not say which body made the announcement, because the excerpt cuts off at that point. It also gives no price, manufacturer, rollout date or comment from any official or patient.

The Washington Times, the right-leaning outlet, runs the story under the headline about a cheap version of the shot raising hopes in low-income countries. It opens with the sentence about the FDA approving a generic version of the world's only twice-a-year HIV prevention shot, and it stresses the 120 countries. The Washington Post, on the left, uses the identical headline and the same opening sentence and stresses the same point about cheaper, faster access. The excerpts show no difference in facts, framing or sources between the two. Neither quotes anyone, names a company, or mentions politics, cost to the U.S. or any criticism. The AP, listed as alternative, also matches both. Its one added detail is that the announcement came on Monday morning. On these excerpts, all three present the story as a global-health access development, and no side's emphasis stands apart.